... nature of IgAN, therapy with mycophenolate mofetil (MMF), a potent immunosuppressive agent, could be effective in patients at risk for progressive disease. In this paper, we discuss the case of an IgAN patient treated with MMF at our center, followed by a review of the literature and our previous...

... Abstract Mycophenolate mophetil (MMP) is a potent immunomodulatory drug that inhibits the function of T and B lymphocytes. It is used successfully in the treatment of recurrent noninfectious uveitis in adults and children. MMF can be used alone or in combination with other immunomodulatory...

... the long-term prognosis of IgAN remains unclear, since it has not yet been tested in acontrolled randomized trial. The role of mycophenolate mofetil (MMF) in IgAN has beenexamined in four major trials. Two prospective randomized studies report no benefit fromMMF. The remaining two studies showed a greater...

...References References 1. Allison AC: Mechanism of action of mycophenolate mofetil. Lupus 2005;14:2-8 2. Tett SE, Saint-Marcoux F, Staaz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, von Gelder T, Cattaneo D: Mycophenolate, clinical pharmacokinetics, formulations and methods...

...: Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543-549. 11. Pozzi C, Bolasco PG, Fogazzi GB, et al: Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-887. 12. Cheng J, Zhang X, Tian J, et al: Combination therapy...

... Nephrol 2016;27:2929-2939. 13. Zehar M, Doria A, Lan J, et al: Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011;20:1484-1493. 14. Thong B, Olsen NJ: Systemic lupus erythematosus...

... for adult patients?. Nephrol Dial Transplant 1999;14:1097-1099 17. Pozzi C, Andrulli S, Pani A, et al: Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 18. Nowack R, Birck R, van der Woude FJ: Mycophenolate mofetil for systemic...

... of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513. 13. Larkin G, Lightman S: Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999;106:370-374. 14. Thorne JE, Jabs DA, Qazi...

..., Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME: Lupus nephritis: a critical review. Autoimmun Rev 2012;12:174-194. 19. Li X, Ren H, Zhang QY, Zhang W, Wu XJ, Xu YW, Shen PY, Chen N: Mycophenolate mofetil, tacrolimus and intravenous cyclophosphamide for the induction treatment of active lupus...

.... Thorne JE, et al: Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005;112:1472-1477 9. Teoh SC, et al: Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008;146:752-760760e1-e3 10. Choudhary A, et al: Mycophenolate mofetil as an immunosuppressive...

.... Mycophenolate mofetil reduces proteinuria by up to 30% and favorably impacts renal survival in Chinese patients with mild histologic lesions, but these results were not achieved in Caucasians with more advanced disease. In conclusion, the choice of immunomodulatory therapy remains controversial. We advocate...

....1996;523:165-168. 34. Tsuruya K, Harada A, Hirakata H, et al: Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy. Clin Nephrol 2000;53:1-9. 35. Chen X, Chen P, Cai G, et al: A randomized control trial of mycophenolate mofetil...

... an induction phase, followed by a maintenance phase ( http://tts.org/kdigo/downloads/kdigo/KDIGO_KidneyTxGuideline.pdf. ). The induction phase includes antibodies blocking T cell activation and a conventional immunosuppressive therapy, associating frequently a calcineurin inhibitor, mycophenolate mofetil...

... concepts such as induction therapy and maintenance therapy. In LN induction therapy until recently, cyclophosphamide in combination with prednisone (PSL) has been the standard method of treatment for proliferative forms of LN. In the latest review, the combination of mycophenolate mofetil (MMF) is also...

...% of patients in this study discontinued treatment due to side effects, the most common being gastrointestinal upset, bone marrow suppression or elevated liver enzymes. Mycophenolate mofetil is a selective purine synthesis inhibitor which is also used to treat organ transplant rejection as well...

.... Pediatr Dermatol 2003; 20: 531-534 21. Grundmann-Kollmann M Korting HC Behrens S Leiter U Krähn G Kaufmann R Peter RU Kerscher M: Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol 1999; 141: 175-176 22. Grundmann-Kollmann M Podda M...

... Nephritis The treatment of severe lupus nephritis has been extensively reviewed recently [ 18 ]. Cyclophosphamide is reserved for high-risk patients with proliferative lupus nephritis, such as crescentic lupus nephritis. Both mycophenolate mofetil and tacrolimus are possible alternatives to intravenous...

... ocular disease. Further clinical studies are required to expand on their use in uveitis patients. Antimetabolites Mycophenolate Mofetil Key Features, Introduction and History Mycophenolate mofetil (MMF) is a prodrug of the mycophenolic acid derived from the fungus Penicillium stoloniferum...

... control, antiplatelet and anticoagulant drugs, statins, and allopurinol. In progressive IgAN patients whose clinical and pathological manifestations are more severe, active therapy may be considered including glucocorticoid therapy, cyclophosphamide, azathioprine, mycophenolate mofetil, tacrolimus...